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ABSTRACT 
 
 
 
Parkinson’s disease (PD) is characterized by a progressive failure of 
mitochondrial respiratory function and subsequent loss of dopaminergic 
neurons, which results in severe neuromuscular deficits. Additionally, 
patients with PD may have visual function abnormalities. The MitoPark 
(MP) mouse is an experimental model of PD created by disrupting 
mitochondrial function in dopamine-producing neurons. MitoPark mice 
develop motor symptoms of PD, but it is currently unknown whether 
abnormalities in retinal function and structure exist.  The objective of this 
study was to determine whether the retina of MP mice demonstrates any 
visual system abnormalities. 
Retinal function of 5 symptomatic MP mice, and 5 age-matched wild 
type (WT) mice was evaluated by full field electroretinography (ERG) at 
varying light intensities following both dark (scotopic) and light (photopic) 
adaptation.  Comparison between the full field ERG a- and b-wave 
components of MP and WT mice were performed. Animals were 
subsequently euthanized and the eyes were prepared for standard 
histopathologic and immunohistochemical analyses. Immunohistochemistry 
was performed on retinal tissues using antibodies against Glial Fibrillary 
Acidic Protein (GFAP) and Tyrosine Hydroxylase (TH), which are markers 
of retinal stress and dopaminergic cells respectively. 
vi 
 
Minor alterations of retinal function were observed in the onset, or 
implicit time, of b-wave formation in the MP mouse, most notably at the 
highest intensity 
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of light tested. Further, the MitoPark mouse had smaller wave amplitudes 
than WT mice, but these observations did not reach statistical significance. 
The histological analyses show that although retinal thickness tended to be 
decreased in the MP mouse, there were no obvious differences in retinal 
architecture or in GFAP and TH staining between the two groups. Using a 
multivariate linear mixed model which included retinal thickness, implicit time 
and mouse type (i.e., either MP or WT),  MP mice exhibited a significantly 
shorter b- wave implicit time at the highest light intensity tested (10 cd·s/m2) 
in the scotopic recordings. These results suggest that there are changes in 
the retinal synaptic architecture of the MP mouse which is both reflected in 
the retinal thickness and electrical signaling of the retina under conditions 
which stimulate the rod and cone photoreceptors.  It would be beneficial to 
evaluate more mice to strengthen the general trends observed in this study. 
The following chapter will briefly discuss ocular anatomy and 
electroretinography that serves as the foundation of my thesis. 
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CHAPTER I. GENERAL INTRODUCTION 
 
 
 
Structure of the Eye 
 
The eye is a forward extension of the central nervous system which 
allows an individual to monitor its surround by utilizing the emission and 
reflection of light energy (Figure I). The basic structure of the eye in 
vertebrates is similar across species. The eye, or the globe, is composed of 
three basic layers. The outer coat is a fibrous tunic which is comprised of 
the sclera and the cornea. The fibrous sclera gives the globe a constant 
shape and form and also provides physical protection and attachment points 
for the extra-ocular muscles to allow for movement of the globe. The 
cornea, which is the most anterior aspect of the fibrous tunic is transparent 
which allows light to pass through. The cornea has a high refractive index 
which focuses light rays centrally towards the visual axis of the eye. The 
second layer of the eye is the vascular tunic, or uveal tract, which is a highly 
vascularized structure. The uveal tract is further divided into the choroid, 
ciliary body and iris. The iris is comprised of vascular connective tissue 
which provides nourishment, waste removal and functions to modify the 
amount of light, by indirect change in pupil diameter, allowed into the back 
of the eye. The lens further refracts light and alteration of the lens curvature 
via the ciliary body allows for the focusing in near and far fields. The central 
layer or tunic of the eye is the neural tunic and is comprised of the retina 
and associated optic nerve. The retina transduces the light into electrical 
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signals, a process termed photo transduction, which is then propagated 
through the neuroretina to ultimately terminate in higher visual centers (i.e., 
the visual cortex in the brain). The three tunics surround the transparent 
media within the eye: the aqueous humor, lens and vitreous humor. The 
transparent media within the eye collectively function to transmit and refract 
light onto the retina. The transparent media also provides an internal 
pressure that helps maintain the shape of the globe. 
 
 
Anatomy and Physiology of the Retina 
 
 
 
The retina is a multi-layer organ and includes five main types of 
nerve cells, two varieties of non-neuronal cells, and two principal synaptic 
layers. Figure II is a representative diagram of the important retinal cells for 
this discussion. The five main types of nerve cells of the retina include 
photoreceptors (rods and cones), horizontal, bipolar, amacrine, and retinal 
ganglion cells (RGCs). The inner and outer plexiform layers are synaptic 
layers where information passes from one retinal cell to the next.  As such, 
they are sandwiched in between the retinal cell layers (nuclear layers). 
Incident light transverses the many retinal layers and unmyelinated 
fibers before striking the light-sensitive photoreceptors, called the rods and 
cones. The visual impulse initiated in the photoreceptor cells is carried to 
the visual centers by a pathway of two additional radially oriented neurons: 
the bipolar cells and the RGCs. The axons of the RGCs form the optic 
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nerve. The bipolar cells are located within the inner nuclear layer (INL) and 
are deemed to be an intraretinal interneuron. There are three types of 
bipolar cells, and they can be distinguished by their connections with the 
photoreceptor cells (1). Briefly, there are depolarizing bipolar cells (ON-
response) which depolarize under stimulation of light. ON-response bipolar 
cells receive input from either rod or cone photoreceptors. There are also 
hyperpolarizing bipolar cells (OFF-response) which do not propagate an 
electrical signal in the presence of light. 
Horizontal or lateral neurotransmission mediated by neurons in the 
OPL and INL play a critical role in shaping the temporal and spatial qualities 
of scotopic (dark) and photopic (light) vision. The horizontal cells are at the 
first synapse in the OPL and modify the response between the 
photoreceptor and bipolar cells. Horizontal cells form triads, composed of a 
presynaptic photoreceptor axon terminal and three postsynaptic dendrites: 
one of a BP cell and two of horizontal cells. Two subtypes of horizontal cells 
have been described(1). Horizontal cells form a network, coupled laterally by 
cell junctions which allows for a rapid exchange of electrical current and 
small molecules (1). 
Another major cell responsible for lateral neurotransmission is the 
amacrine cell and a subtype of cells called the interplexiform cells (IPcs). The 
amacrine cells reside in the second synapse, the INL, and provide a 
connection between bipolar and RGCs.  Amacrine cell processes form 
dyads composed of one presynaptic bipolar axon terminal and two 
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postsynaptic dendrites to one ganglion cell and one fellow amacrine cell (1). 
There are several classification schemes which have been used to describe 
the different types of amacrine cells (1, 2). Functionally, amacrine cells 
serve to increase the sensitivity of ganglion cells to changes in illumination, 
thus contributing to motion, direction, and contrast discrimination. The 
interplexiform amacrine cells are a subtype of amacrine cells that constitute 
a group of long-range feedback neurons that modulate information. This 
specialized neuron has its soma within the INL and forms a feedback 
pathway, mainly presynaptic, on horizontal cells (3). This regulatory loop 
acts on horizontal cell regulating the diameter of receptive fields and 
subsequently, the bipolar cells (1). 
Glutamate, an excitatory neurotransmitter, serves as the principal 
vertical neurotransmitter of the retina (4, 5). Glutamate plays an important 
role in vertical transmission of electrical signal from the photoreceptors, 
bipolar cells to the RGCs. Under dark conditions, photoreceptors are 
continuously depolarizing and releasing glutamate. Briefly, when the 
photoreceptors perceive light stimulus, glutamate release from these cells 
decreases, which prompts transmission of the signal up to the second-order 
retinal neurons as post synaptic glutamate receptors of BP cells are 
inhibitory. 
The main inhibitory transmitter in the retina is gamma Amino Butyric 
Acid (GABA) (6). Gamma Amino Butyric Acid is utilized by both horizontal 
and amacrine cells for lateral processing of the signal which has an 
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 inhibitory function in the OPL and IPL, respectively. Together with glycine, 
GABA acts to inhibit ganglion cells by opening Cl- channels on retinal 
neurons (7). 
Dopamine, an abundant catecholamine in the retina, is contained 
within the amacrine and interplexiform cells (1, 8). Dopamine containing cells 
have been identified in the rodent and human retina using an antibody 
directed to tyrosine hydroxylase (TH), the biosynthetic enzyme which 
produces dopamine (DA) (1, 9). Dopamine has been established to function 
as a major neurotransmitter and neuromodulator in vertebrate retina (1, 10). 
Dopamine decreases horizontal cell-gap junction permeability and 
consequently narrows the receptive field which aids in visual contrast 
sensitivity while GABA increases permeability and widens the receptive field 
of horizontal cells(1). Modulation of information occurs by the interplexiform 
cells occurs via glycine, dopamine or gamma-aminobutyric (GABA) (11). 
 
 
The Full Field Electroretinogram 
 
 
 
Electrodiagnostic testing provides a unique, noninvasive opportunity 
for researchers to objectively evaluate the visual system. An 
electroretinogram (ERG) is a recording of the cumulative electric potentials 
of the retina generated to a standardized light stimulus (12). An ERG is a 
compound electrical wave arising from the activity of different cells within 
the neuronal layers of the retina. The wave form of the ERG is affected not 
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only by the intensity and duration of the stimulus but also by wavelength. 
The ERG can be recorded in scotopic (dark adapted) conditions to assess 
the rod or mixed rod-cone functions and in photopic condition (light 
adapted) to investigate the cone system (12). 
Measurement of the amplitude and implicit time generated from retinal 
responses to visual stimuli can help determine the integrity of the functional 
retina. The ERG provides objective results and assists in characterizing the 
function of specific cell types within the retina. 
 
Full field ERG tracings are typically comprised of two major 
components. Values reported are the implicit times (milliseconds) and 
amplitude (microvolts) for the major components (See figure III). The first 
wave is the a-wave. It is the first negative deflection, or hyperpolarization, 
representing mainly the intracellular charge of the photoreceptors caused 
by light-evoked closure of the sodium channels on the cell membranes (13, 
14). The amplitude of the a-wave is measured from the baseline to the 
trough of the a-wave. The a-wave implicit time refers to the time between 
stimulus onset and the trough of the a-wave. The hyperpolarization 
diminishes the release of neurotransmitter, which in turn activates bipolar 
cells. 
The b-wave is the positive deflection of the fERG and is primarily 
generated by bipolar cells (13, 15, 16). The amplitude of the b-wave is 
measured from the trough of the a-wave to the peak of the b-wave. Implicit 
time of the b- wave is measured from the onset of the stimulus to the peak 
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of the b-wave. On the ascending portion of the b-wave, a series of high-
frequency wavelets, called oscillatory potentials (OPs), can be observed. 
The exact origin of these wavelets is still unclear, but it is thought that they 
arise from the interaction between amacrine and bipolar cells (17, 18). The 
flash ERG is used to assess mainly the function of the photoreceptors and 
bipolar cells, or the outer and mid-retinal function of the retina (18, 19). 
Different stimuli and recording paradigms will allow separation of 
responses contributed by different types of cells in the retina. The 
International Society for Clinical Electrophysiology of Vision (ISCEV) 
provides recommendations for standardized protocols so that comparable 
ERGs could be recorded throughout the world (20). In their recommended 
standards, the following responses, named according to conditions of 
adaptation and stimulus (flash strength in cd·s/m2) are as follows: Dark-
adapted 0.01 ERG (“rod response”), Dark-adapted 3.0 ERG (“maximal or 
standard combined rod-cone response”), Dark-adapted 3.0 Oscillatory 
potentials, Light-adapted 3.0 ERG (“single-flash cone response”), Light-
adapted 3.0 flicker ERG, and recommended additional response testing of 
either Dark-adapted 10.0 ERG or Dark-adapted 
30.0 ERG. Although the separation of different components is usually not 
complete, enhancing responses driven by one system and suppressing 
responses from other systems in the retina helps to increase the diagnostic  
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value of the FERG. Varying the stimulus and background light wavelengths 
and intensities, stimulus duration and frequency enhances different 
components of the FERG (20). 
 
 
Thesis Organization 
 
 
 
In chapter II this thesis provides an introduction to Parkinson’s 
disease and summarizes relevant animal models, including the MitoPark 
mouse which was used in this study to evaluate retinal function and 
structure. Next, chapter III describes the observed retinal structure and 
function of MP mice exhibiting motor symptoms of PD. Lastly, chapter IV 
summarizes the findings and concludes with recommendations for future 
research. 
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Figures for chapter I 
 
 
 
 
 
 
 
 
Figure I. General anatomy of the eye. 
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Figure II. Cross-section of the retina demonstrating the principal 
cell types involved in retinal signaling. 
Key: RPE = Retinal Pigmented Epithelium; PRs = Photoreceptors; 
ONL = Outer Nuclear Layer; OPL = Outer Plexiform Layer; INL = Inner 
Nuclear Layer; IPL = Inner Plexiform Layer; RGCL = Retinal Ganglion Cell 
Layer. 
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Figure III. Examples of photopic and scotopic ERG recordings. 
Figure III represents an example of scotopic ERG trace 
in a mouse. The red arrow indicate flash onset. The a-wave 
amplitude (first blue solid arrow bar) is measured from the pre-
stimulus, or baseline, to the trough of the a-wave, and the b-
wave amplitude (second solid black arrow bar) is measured 
from the trough    of the a-wave to the peak of the b-wave. The 
oscillatory potentials can be observed on the ascending part of 
the b-wave. The implicit time of the a-wave (first dashed blue 
arrow bar) refers to the time between stimulus onset and the 
trough of the a-wave whereas the b-wave implicit time (second 
dashed black arrow bar) is measured from the onset of the 
stimulus to the peak of the b-wave. 
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CHAPTER II. LITERATURE REVIEW 
 
 
 
An Introduction to Parkinson’s Disease 
 
 
 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder, behind Alzheimer’s, with a prevalence of 0.3% 
and has an estimated incidence of 8-18 per 100,000 cases per year (2, 21). 
The prevalence of PD increases with age, with approximately 1% in the 
over 60 (22, 23) and 4% in the over 80 year old population being affected  
(21). Parkinson’s disease is characterized by selective and progressive 
degeneration of mesencephalic dopaminergic (DA) neurons and 
neurotransmitter in the substantia nigra compacta (SNpc) and striatal 
dopamine depletion (24, 25) . Like many neurodegenerative diseases, the 
cause of PD is not known, but it is thought to be due to a complex 
interaction among multiple predisposing genes and environmental 
contributions (26). Most cases of PD are sporadic, or idiopathic; however 
there are a few rare familial forms that have been described (27). The first 
report of PD, described by James Parkinson in 1817, focused on the 
cardinal signs of motor dysfunction in patients, including resting tremors, 
bradykinesia, impaired balance and rigidity (28). The basal ganglia, located 
within the brain, are affected in individuals with PD. The basal ganglia are  
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associated with a variety of functions including the control of voluntary 
movement, procedural learning, routine behaviors, eye movements, 
cognition and emotion. 
Since PD was first described, neural circuits that extend beyond the 
basal ganglia have been identified as part of the PD neurodegenerative 
disorder, and therefore PD is now considered to be a multi-system disease 
(2). There are many non-motor symptoms associated with PD that can 
appear well before the onset of the motor phenotype (29-31).  Non-motor 
symptoms, similar to the classically described motor symptoms, can also 
play a significant role in quality of life for PD patients. Common non-motor 
symptoms of PD can include depression, apathy, hyposomnia, impaired 
cognition and autonomic failure including gastrointestinal and sensory 
dysfunction (2, 29-33). Sensory dysfunction may include loss of smell, 
auditory issues, ‘restless leg’ syndrome, and visual dysfunction. 
The mitochondrial theory of aging remains one of the most prominent 
hypotheses for the gradual decline of an organism’s fitness with age (34) 
and may help explain the changes seen in patients with PD. Animal models 
of mitochondrial dysfunction have been successful in replicating a number 
of the phenotypic traits associated with normal aging such as weight loss, 
reduced subcutaneous fat, alopecia, kyphosis, osteoporosis, anemia, 
reduced fertility and heart enlargement (35). Specific to retinal disease, 
studies have indicated that increased mitochondrial DNA damage is 
associated with age related macular degeneration (36, 37), late stage 
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retinitis pigmentosa (38) and degeneration of retinal ganglion cells in certain 
disease conditions (39). These findings indicate a potential link between 
mitochondrial dysfunction and progression of retinal diseases (34). 
 
 
Evidence for Visual Dysfunction in Parkinson’s Disease 
 
 
 
The physiologic abnormalities resulting from DA neuron 
degeneration in the central nervous system extends to the visual pathways 
in PD (24). Visual dysfunction is thought to occur at several levels of the 
visual pathway, supported by evidence of psychophysical, 
electrophysiological, and morphologic disruption of retinal structure and 
function (2). For example, in some PD patients there is evidence to support 
electrophysiological deficits in visual information processing from the retina 
to the primary cortex (33, 40). Perceptual defects like abnormal vision-
evoked potentials can be recognized in PD patients and in the monkey 
model (41, 42). Electrophysiological as well as spatial and temporal 
contrast sensitivity measurements suggest that visual dysfunction is 
caused be a degeneration of DA neurons (42). Post-mortem assays for DA 
in the retina showed severe degeneration of the foveal DA innervation in 
PD patients (24). 
Common visual symptoms in patients with PD can range from 
complaints of dry eye (43), visual acuity loss (44-47), reduced color 
discrimination(48, 49), perceptual disturbances (i.e., orientation motion 
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perception (50), facial perception (51) and complex visual hallucinations(47, 
52) and have been studied extensively (2, 32, 46, 53-55). Such visual 
symptoms are a considerable cause of morbidity in PD (56), and with 
respect to visual hallucinations, are an important predictor of cognitive 
decline as well as institutional care and mortality (57-60). Animal models 
have been developed in an effort to study the multi-system nature of PD, as 
understanding this may help achieve early diagnosis of disease and may 
help understand the pathophysiology of the disease (61). 
 
 
Animal Models of Parkinson’s Disease 
 
 
 
Parkinson’s disease patients have been observed to possess 
frequent mitochondrial defects in the affected DA neurons (62, 63). There is 
a higher susceptibility of DA neurons to mitochondrial dysfunction and the 
resultant generation of reactive oxygen species when compared to other 
neurons (27). Toxins used to create PD animal models, such as 6-
hydroxydopamine (6-OHDA) and 1 methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), inhibit mitochondrial function, which in turn 
impairs cellular energy generation and subsequently causes acute damage 
(i.e., death) to midbrain DA neurons and severe motor impairment (63).  
This results in work-related cellular injury occurring from the generation of 
reactive oxygen species which occur when ATP supply does not meet 
demand. 
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The classical preclinical toxin based models of PD use 6-OHDA and 
MPTP to induce selective loss of DA neurons in the SNpc (25, 63), and 
produce similar biochemical and neuropathological defects as those in PD 
patients Both of these toxic compounds cause acute damage to midbrain 
DA neurons, severe motor impairment and a sudden decrease in striatal 
DA levels (27, 63). Both MPTP and 6-OHDA have been shown to quickly 
induce degeneration of retinal DA amacrine interneurons in various animal 
models (64-69). Since there are near instantaneous effects of MPTP and 6-
OHDA on rodent models, high inter- animal variability and potential for 
systemic toxicity (62), there is a limit to their use in studies focused on the 
development and progression of PD. 
Genetic linkage studies of PD in humans have also led to the 
development of transgenic mouse models for the study of PD. In brief, 
mouse models have provided insight into the pathogenic role of specific 
genes, such as α-synuclein, leucine-rich repeat kinase 2 (LRRK2) and 
parkin within the context of familial forms of PD (27, 70). Knockout mice 
with deletion of parkin, Dj-1 or PINK1 genes have been generated (71-73), 
as have mice overexpressing mutant forms of human α-synuclein (74). 
These genetic models result in only minor motor impairment with little or no 
nigrostriatal DA degeneration. Nevertheless, mouse models based on 
inactivation or mutations in known PD genes provide valuable information  
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on the causes and mechanisms of PD development, as disease etiology 
and progression is expected to be a combination of genetic and 
environmental factors (27). 
In studies examining PD patients versus age-matched controls, 
higher numbers of respiratory chain deficient dopamine neurons were found 
in patients with PD than in their age-matched counterparts (75). In the 
MitoPark (MP) mouse model (DAT+/cre –TfamloxP/loxP), DA neurons are 
rendered respiratory chain deficient by cell type-specific inactivation of 
mitochondrial transcription factor A (Tfam), which is a protein essential for 
mitochondrial DNA expression and maintenance (76-80). Targeting the 
genetic lesion to dopaminergic neurons alone is accomplished by utilizing 
the dopamine transporter gene locus which is activated only in DA cells. The 
severe respiratory chain deficiency which results is demonstrated by 
evidence of decreased mitochondrial DNA (mtDNA) encoded cytochrome c 
oxidase (COX) subunit I transcripts and reduced COX enzyme activity (81) 
in midbrain DA neurons in this model. 
The MP mouse model demonstrates clinical, or phenotypical, features 
of PD including adult onset of neurodegeneration, progressive phenotypic 
decline in motor function, presence of intraneuronal inclusions, earlier onset 
and more extensive cell death in the SNpc than in the VTA and altered 
responsiveness to levodopa (L-DOPA) treatment dependent upon the 
disease stage (81-83). 
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The MP mouse model provides researchers with a more than a 30 
week time window during which the process of nigrostriatal DA neuron loss 
and related secondary changes in neurocircuitry can be studied. MitoPark 
mice appear normal at birth with no increased embryonic or neonatal 
lethality and show no PD like symptoms at weaning or as young adults (82). 
Locomotion deficits progress and at 20 weeks the mice start to display 
more evident phenotypic PD manifestations such as tremor, twitching and 
abnormal gait. By 30 weeks there are severe motor deficits. MitoPark mice 
are usually euthanized around 45 weeks because of their poor general 
condition (81, 82). 
 
 
Conclusions 
 
 
 
The MP mouse model demonstrates phenotypical features of PD 
including adult onset neurodegeneration and progressive phenotypic decline 
in motor function evident by tremors, twitching and abnormal gait. Visual 
function abnormalities similar to those reported in humans have not been 
evaluated in the MP mouse model. It would be beneficial to determine, 
using flash electroretinogram recordings, whether retinal function 
abnormalities exist in a mouse model of PD that is displaying phenotypical 
signs of motor dysfunction, and if so, whether these are similar to the 
human disease. Since the available evidence suggests that humans with 
PD often exhibit decreased amplitudes and prolonged implicit times of fERG 
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b- waves, we anticipate that a mouse model developed to reflect the 
dopaminergic motor dysfunction of humans will display similar non-motor 
dopaminergic dysfunction. 
 
Furthermore, we are interested in relating potential alterations in 
retinal structure to functional changes in this murine model. Correlating 
retinal structure and functional changes may help clarify the potential 
trophic role of dopamine in maintaining retinal structure and function. 
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CHAPTER III. EVALUATION OF RETINAL FUNCTION AND STRUCTURE 
IN A PARKINSON’S DISEASE MURINE MODEL 
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Abstract: 
 
Objective. Parkinson’s disease (PD) is characterized by a progressive 
failure of mitochondrial respiratory function and subsequent loss of 
dopaminergic neurons, which results in severe neuromuscular deficits. 
Additionally, PD patients often have abnormalities in visual function. The 
MitoPark (MP) mouse is a PD model created by targeted disruption of 
mitochondrial function in dopamine-producing neurons. MitoPark mice 
develop motor symptoms similar to human PD, but it is currently unknown 
whether abnormalities occur in retinal function and structure. The objective 
of this study is to evaluate functional and structural changes to the retina of 
MP mice. 
Methods. Retinal function of 5 symptomatic MP and 5 age-matched 
wild type mice was evaluated following overnight dark adaptation using 
full field electroretinography (ERG) with intensities of 0.0003, 0.01, 1, 3 
and 10 cd·s/m2,
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as well as at 3 cd·s/m2 following 10 minutes of light adaptation. Retinal 
 
staining, supplemented by immunohistochemistry for glial acid fibrillary 
protein (GFAP) and tyrosine hydroxylase (TH). Comparison between the full 
field ERG a- and b-wave components of MP and WT mice and retinal 
measurements was performed using a mixed model linear regression. 
Results. The results of the scotopic and photopic full field ERG showed no 
statistically significant changes in a- and b-wave amplitudes; however, the 
b- wave amplitude tended to be lower in MP mice compared to WT at all 
tested light intensity levels.  The a-wave implicit time was not different 
between the groups. 
In contrast, the MP mice exhibited tendency towards both an increased b-
wave implicit time at 0.0003 cd·s/m2 illumination (p =0.06) and a shorter 
implicit time at 10 cd·s/m2 illumination (p=0.05) compared to WT.  No 
obvious difference in retinal architecture was observed between MP and 
WT mice, although MP mice 
tended to have thinner retinas. Immunohistochemistry revealed strong TH 
staining in the inner plexiform layer in both mouse types. No GFAP staining 
was observed in either group. When retinal thickness was included as a 
variable in multivariate linear analysis, MP mice had significantly shorter 
implicit times (p=0.03) when compared to WT mice at the highest light 
intensity tested under scotopic conditions. 
Conclusions.  The retinal functional changes observed in MP mice are 
consistent with a delay of the initiation of electrical transmission vertically 
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through the outer retina at low light intensities and without significant 
effects on the ultimate b-wave amplitudes generated. In contrast, b- wave 
implicit time is decreased at the highest light intensity tested, but without 
effects on the ultimate wave amplitude generated. The MP model does not 
show significant retinal neuronal losses when motor symptoms of 
Parkinson’s disease are manifest. However, there is a trend for reduced 
retinal thickness in the MP mouse which may be the result of subtle retinal 
cell losses. The shortened implicit time of b- wave formation at 10 cd·s/m2 
suggests that the retinal neurons affected in the MP mouse are inhibitory 
neurons within the retina. Further studies with increased number of mice 
are needed to clarify the physiologic significance of the differences 
observed between the groups. 
 
 
Key Words: MitoPark mouse model, retinal degeneration, Parkinson’s 
disease, amacrine cell, interplexiform cell, flash electroretinogram 
 
 
Introduction: 
 
Parkinson’s disease (PD) is characterized by striatal dopamine 
depletion caused by a progressive degeneration of mesencephalic 
dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) 
(1, 2). Like many neurodegenerative diseases, the etiology of PD is 
unknown, but is hypothesized to arise from a combination of genetic and 
environmental factors that result in neuronal mitochondrial dysfunction (3). 
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This metabolic abnormality ultimately results in DA neuron degeneration in 
the central nervous system, and also occurs in the retina, as 
electrophysiological and functional testing have demonstrated perceptual 
deficits in PD patients and in experimental animal models (4, 5). Further, 
the observed abnormal processing of visual information has been 
correlated to decreased retinal levels of dopamine and its rate-limiting 
synthesizing enzyme tyrosine hydroxylase in dopaminergic nerve 
processes in parkinsonian humans (6-8) and toxin-based (e.g., 1-Methyl-
4-phenyl-1,2,3,6- tetrahydropyridine, or MPTP) in animal models (9, 10). 
Retinal DA concentration has also been documented to be decreased in 
post-mortem tissue from PD patients(7). As a result of neuronal losses, 
optical coherence tomography has shown retinal thinning of the macular 
region and inner retina of human PD cases (11). Additionally, 
electrophysiological retinal measurements (e.g., full field 
electroretinography), in addition to spatial and temporal contrast sensitivity 
measurements, help support the hypothesis that visual dysfunction in PD is 
related to the degeneration of DA neurons (5). The flash electroretinogram 
(fERG) is a tool utilized to evaluate the functionality of the outer retina, 
mainly photoreceptors and bipolar cells. In PD fERG amplitudes in human 
patients have predominantly been documented to be decreased (12-16) 
and have prolonged implicit, i.e., wave onset, times. 
Since TH is the rate limiting enzyme in the synthesis of DA, TH 
staining can be used to identify dopaminergic neurons within the retina. In 
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mammalian retinas, TH immunoreactive DA neurons include a subtype of 
amacrine (AII) and the interplexiform cells (6, 17). Dopaminergic amacrine 
cells modulate both rod- and cone-mediated vertical pathways, with 
dopamine playing a crucial role as a chemical messenger in light-to-dark 
adaptation (12, 13). Dopaminergic interplexiform cells send processes to 
both the inner and outer plexiform layers and regulate horizontal cell 
coupling which, in turn, modulates the diameter of horizontal cell receptive 
fields (6). 
Mutations in mitochondrial DNA are known to cause 
neurodegeneration and may help explain, at least in part, PD 
pathophysiology (3, 18). Gradual failure of mitochondrial function leads to 
work-related neuronal injury and ultimately to cell death. The MitoPark (MP) 
mouse model, generated by mitochondrial gene disruption targeted to 
dopamine-producing cells by use of the dopamine transporter gene (18), 
recapitulates many of the phenotypic motor features of human PD, 
including bradykinesia, resting tremor, rigidity and impaired motor balance. 
Progressively declining motor deficits seen in the MP mice are directly 
related to declining numbers of TH-positive cells and fibers which becomes 
severe by 30 weeks of age (18). The MP mouse model is based on direct 
genetic impairment of respiratory chain function in dopamine neurons, and 
therefore may closely resemble the human disease. 
To our knowledge retinal function and structure have not been 
evaluated in the MitoPark murine model. The aim of this study was to 
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characterize the retinal function and structure of symptomatic MP mice by 
means of electroretinography and histopathology, respectively. 
 
Materials and Methods: 
 
 
All experiments were performed in accordance with the guidelines of 
National Institutes of Health Guide for the Care and Use of Laboratory 
Animals and approved by the Iowa State University Animal Care 
Committee #1-12-7281- M (Ames, Iowa, USA). 
Generation of MitoPark mice (DAT+/cre –TfamloxP/loxP) has been 
described 
 
previously (18). The MitoPark mice were obtained from Dr. Anumantha 
Kanthasamy (Department of Biomedical Sciences; Parkinson’s Disorder 
Research Laboratory, Iowa Center for Neurotoxicology; College of 
Veterinary Medicine, Iowa State University; Ames, IA USA). Respective 
wild type (WT) mice of C57bl/6 background (Charles River Laboratories, 
Wilmington, Massachusetts) were used as age- and sex-matched controls 
(n=5). 
A total of five MP mice were used in this study. The females (n=2) 
were between 20-25 weeks of age while male mice (n=3) were 30-35 weeks 
of age. Ages of mice used in this study were determined based on when the 
mice were phenotypically displaying signs of dyskinesia and motor 
incoordination. All MP mice were deemed to be displaying clinical signs of 
motor dysfunction. Mice were housed in standard conditions: 1-3/cage in a 
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humidity controlled (relative, 30%) room and constant temperature (22 +/-
1°C) and a 12-hour light/dark cycle with ad libitum access to food and water. 
 
 
In vivo Electroretinography 
 
 
For in vivo full field electroretinography (fERG), animals were dark- 
adapted for at least 12 hours. All preparations were performed under a dim 
red light. Anesthesia was induced with isoflurane gas and maintained with 
an intraperitoneal injection of ketamine (0.08 mg/1g; Bioniche Teoranta, 
Inverin, Co. Galway, Ireland) and xylazine (0.015 mg/1 g; Lloyd, 
Shenandoah, Iowa, USA) mixture. Animals were then positioned in sternal 
position on a heated table (Roland Consult, Brandenburg, Germany) 
maintained at a constant temperature 37 +/- 1°C. Topical application of 1% 
tropicamide (Bausch and Lomb, Tampa, Florida, USA) was used as a 
mydriatic agent prior to full field ERG recordings. 
For fERG recordings a 2.5 mm gold ring active electrode (Acrivet 
Veterinary Division, Hennigsdorf, Germany) was placed concentrically on 
both corneas after the application of  2.5% Hypromellose Ophthalmic 
Solution (Goniovisc™, HUB Pharmaceuticals Rancho Cucamonga, 
California, USA) to each eye to ensure good contact with the electrodes 
and to prevent desiccation of the corneas. Subdermal needle electrodes 
(Roland Consult, Brandenburg, Germany) placed in the ipsilateral scruff 
and at the base of the tail served as reference and ground electrodes, 
respectively. The RETIanimal software RETIport (Roland Consult, 
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Brandenburg, Germany) generated and controlled the light stimulus. Brief 
single flash stimuli were delivered in a Ganzfeld Q450 dome shielded by a 
custom-made Faraday cage. 
For scotopic recordings, stimuli were elicited by brief flashes of LED 
white light. The ERG was recorded in response to the following stimuli: 
0.0003 cd·s/m2, 0.01 cd·s/m2, 3 cd·s/m2 and 10 cd·s/m2.  For each 0.003 
cd·s/m2 intensity tested, 40 responses were averaged. Five responses were 
averaged for 0.01, 3,0and 10 cd·s/m2 in order to reduce noise. An 
interstimulus interval of 5 seconds was used for the dimmest intensity 
(0.0003 cd·s/m2). For 0.01 cd·s/m2 stimuli an interstimulus interval of 2.1 
was used. An interstimulus interval of 10.5, seconds was used for 3.0 and 
10.0 cd·s/m2 intensities. For photopic recordings, animals were light 
adapted to bright LED white light (30 cd·s/m2) for 10 minutes and the ERG 
was recorded in response to bright flashes of 3 cd·s/m2. Five responses 
were averaged for photopic recordings and there was an interstimulus 
interval of 1.6 seconds between flashes of light with a background intensity 
of 25 cd·s/m2. 
 
 
ERG Data Analysis 
 
 
 
Electroretinogram recordings were analyzed in accordance to the 
International Society for Clinical Electrophysiology of Vision (ISCEV) 
guidelines (19). The a-wave amplitude and implicit time were measured 
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from the baseline to the first negative trough. The b-wave implicit time was 
measured from the baseline to the first positive peak, and the amplitude 
was measured from the first negative trough (the a-wave) to the first 
positive peak. 
 
 
Histologic and Morphometric Analysis of the Retina 
 
 
 
While still under anesthesia at the end of the ERG recordings, the 
mice were humanely euthanized via intraperitoneal injection of 0.1 ml 
pentobarbital/phenytoin sodium solution (Beuthanasia-D Special, 
Intervet/Merck Animal Health). The eyes were collected and then embedded 
and sectioned for histological analysis. Retinal sections were stained with 
hematoxylin and eosin (H&E) and evaluated by light microscopy. Digital 
photographs of the retina were taken using a photomicroscope (Olympus 
BX41 Microscope, Japan, and Olympus DP 20 Camera, Japan). ImageJ 
software (National Institutes of Health) was used for morphometric 
evaluation of the different retinal layers from the photographs. 
Five measurements, at approximately 50 um intervals, were 
performed to measure the IPL, INL, ONL along 250 um of retina located 
near the optic nerve. The entire thickness of the retina, from outer to inner 
limiting membrane was also determined. 
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Statistical Analysis 
 
 
 
The SAS® (Version 9.4, SAS Institute, Cary, NC) Mixed Procedure 
was used to conduct an analysis of variance using a mixed effects model. 
Fixed effects in the first set of analyses included eye, type (MP or WT), 
light intensity, and the two- and three-way interactions, with models 
analyzed by wave form. Fixed effects in the second set of analyses 
included Type, Light Intensity, full retinal thickness, and the two- and three-
way interactions, with models analyzed by waveforms. In both analyses, 
animal was a random effect. When overall significance was found, post 
hoc comparisons were conducted with pairwise t tests of the least-squares 
means. Differences in retinal thickness were assessed using a student’s t-
test for independent samples. All analyses were considered significant at 
p≤0.05 (two tailed). 
 
 
Results 
 
 
 
Electroretinography 
 
 
 
Values for all parameters are tabulated in Appendix B. The a-wave 
implicit time values were similar for both groups of mice under scotopic 
conditions at 3.0 and 10.0 cd·s/m2 and photopic conditions at 3.0 cd·s/m2  
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(p>0.05). Figure I shows the adjusted least square means for scotopic 
recordings of a-wave implicit times at 3 cd·s/m2, 10 cd·s/m2 and photopic 
recordings at 3.0 cd·s/m2. 
The a-wave amplitude values were similar for both groups of mice 
under scotopic conditions of 3.0 and 10.0 cd·s/m2 and photopic recordings 
at 3.0 cd·s/m2 (p>0.05). There is a general trend of delay of the MitoPark 
mouse response at all levels tested. Figure II shows the adjusted least 
square means for scotopic recordings of a- wave amplitude at 3 cd·s/m2, 10 
cd·s/m2 and photopic recording at 3.0 cd·s/m2 . 
The b- wave implicit time approached significant differences 
between groups at 10.0 cd·s/m2 (p = 0.05) and at 0.0003 cd·s/m2 (p=0.06). 
(Fig. III). For the scotopic recordings, the general trend was shortening of 
implicit time (p≥0.05) as stimulus intensity increased except for the WT 
mouse group at 10.0 cd·s/m2. The slopes of the implicit times of each 
group are parallel until higher stimulus intensities, in which the MP mice 
have a shorter implicit time than the WT. The b-wave implicit time for 
intensity 3 cd·s/m2 under photopic conditions was not significant (See 
figure V.A) 
B-wave amplitudes did not significantly differ (p> 0.05) between 
groups, although there was a general trend that MP mice had lower b-wave 
amplitudes compared to WT at all light intensities tested under scotopic 
conditions which included 0.0003 cd·s/m2, 3.0 cd·s/m2 and 10.0 cd·s/m2 . 
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 (See figure IV). The mean b-wave amplitude formation of intensity 3 cd·s/m2 
tested under photopic conditions did not differ between mouse groups (See 
figure V.B). 
 
 
Retinal Histology 
 
 
Representative retina histology images are depicted in Figure VI-A & 
B. The average retinal thickness (± standard deviation) although less in the 
MP mouse, did not differ significantly between mouse group (See Table I 
and Figure VII).The total thickness of the retina was 126.94 (±20.61) µm for 
the WT mice group and 112.63 (±22.44) µm for the MP mouse group. 
Reported thickness for the INL was 27.34 (±9.62) µm and 23.17 (±4.48) 
µm for the WT and MP mice, respectively. Measurements for IPL were 
43.61 (±11.57) µm and 34.41 (±7.33) 
µm for the WT and MP, respectively. Lastly, measurements for ONL were 
42.08 (±9.66) µm and 37.55 (±6.08) µm, respectively. The immunohistologic 
staining for GFAP revealed little or no detectable GFAP in any of the retinal 
sections (Data not shown). Tyrosine hydroxylase staining revealed no 
appreciable differences between mouse groups (Figure VIII A, B). 
 
 
 
 
 
 
 
 
 
40  
 
Combination of b-wave Implicit Time and Full Thickness Retinal Values 
 
 
 
When full retinal thickness was incorporated into the linear model, 
significant differences between mouse groups was seen at the highest light 
intensity tested (p = 0.03) (Figure IX). 
 
 
 
Evaluation of b-wave implicit time at 10 cd·s/m2 
 
 
Given the significance of b-wave implicit time and full retinal thickness at the 
highest light intensity tested, further evaluation of the data for that individual 
intensity was evaluated using an unpaired t-test. Significant differences 
between mouse groups were seen (p=0.008) (Figure X). 
 
 
Discussion 
 
 
 
To the best of our knowledge, this is the first study which has 
evaluated retinal function and structure of the retina in the MitoPark mouse 
model. We characterized the full field ERG response in MitoPark mice at an 
age in which they were phenotypically displaying signs consistent with 
Parkinson’s disease- like symptoms, such as obvious resting tremors, 
rigidity and impaired motor balance. There were no appreciable differences in 
amplitude of the a- or b- waves, indicating that photoreceptor and bipolar 
neuron response, respectively, to the stimulus were not overtly affected. 
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However, the shorter implicit time of the b-wave at the highest light intensity 
tested (10 cd·s/m2) in the MP group compared to WT group suggests that 
there are alterations in the retinal synaptic interconnectivity, e.g., 
dopaminergic interplexiform neurons, in the MP mouse model that affects 
the function outer retina. 
 
Although MP animals were studied when they exhibited clear 
neurological symptoms consistent with the loss of dopamine neurons 
modulating the neuromuscular system, no clear dropout of retinal 
dopaminergic neurons was appreciated when evaluating TH staining in the 
MP compared to WT mouse groups. Furthermore, a lack of GFAP 
immunoreactivity, a marker of glial response to injury(20), is consistent with 
a lack of retinal injury in the MP mouse. In sum, these results show that 
although the MP model has a targeted injury of mitochondria in 
dopaminergic neurons, there is no major anatomical lesion within the retina 
comparable to the massive injury in the motor system. This is surprising as 
retinal neurons are generally have a high metabolic rate and ATP 
production, which would lead rapidly to cellular injury due to metabolic work- 
related injury from free radical production (21, 22). This reasoning suggests 
that the dopaminergic neurons within the retina do not have an inherently 
high metabolic rate which would account for the lack of injury in this model. 
This concept is supported by the observation that chemically-induced 
mitochondrial dysfunction which leads to loss of dopaminergic neurons in 
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the striatum and produces parkonsonian symptoms, e.g., MTPT, does not 
have any observable effect on dopamine producing cells in the retina (2) . 
Another potential explanation is that the MP mice used in the study were 
not old enough to have evident changes such as changes in GFAP or TH 
immunoreactivity of amacrine cells. MitoPark mice typically have to be 
sacrificed around 45 weeks of age due to weight loss and poor general 
condition (18). This is in contrast to the motor neurons of the basal ganglia 
which succumb quickly, degenerate, and cause obvious phenotypical motor 
impairment in the MP mouse (18, 23). As similarly seen in toxin-based 
animal models for PD, discrepancies between the presence or absence in 
amacrine cell death appeared to be the result of different model paradigms: 
long term applications of systemic MPTP over 2 years resulted in dramatic 
decrease in TH-expression and DA amacrine cell loss (24) compared to 
one-time local application of 6-OHDA and short term intraperitoneal 
injections of MPTP which did not result in loss TH immunoreactivity (2). 
However, the slightly reduced mean retinal thickness in the MP group 
could arise from the loss of a small number of dopaminergic neurons and/or 
their processes which would not be detectable on gross examination. This 
hypothesis is supported by the finding that retinal thickness was in fact a 
significant independent variable when included in the mixed linear model 
with mouse type, individual mouse, and light intensity as covariants. The 
results show that at low light intensities there was no significant difference 
between the groups. However, under scoptic conditions of higher light 
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intensity (10 cd·s/m2), in which both the rod and cone system are 
stimulated, the implicit time of the b-wave was significantly reduced. This 
could imply that a loss of inhibitory dopaminergic neurons which ordinarily 
are involved in the processing of retinal electrical information under brighter 
illumination. 
Alternatively, the impairment in mitochondrial energy production due to 
insufficient cytochrome c oxidase activity (and subsequent ATP generation) 
produced by the gene targeting of the MP model may provide a functional 
defect in selected dopamine-containing amacrine cells under a high level of 
photic stimulation. Future research should evaluate whether synaptic or 
neurochemical remodeling occurs in the MP model in response to sustained 
high levels of neuronal activity and subsequent metabolic stress within the 
retina. 
 
 
Conclusions 
 
 
In summary, the MP mouse does not demonstrate obvious dopamine- 
containing amacrine cell losses and thus fails to reproduce fERG changes 
that have been reported in human patients and chronic animal models. 
However, this model does bring to the forefront the possibility of inhibitory 
dopaminergic interneurons of the retina are affected and therefore, in turn, 
the implicit time b- wave formation is affected. Perhaps the mice are not old 
enough to have as severe dopamine damage evident in the retina as in the 
mesencephalon. The amacrine cells are protected in some fashion, and do 
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not succumb to degeneration seen with other cells that are comprised of 
dopamine in the midbrain. Since it is thought that PD in humans is a 
combination of genetic and environmental factors, a single animal model will 
probably never be ideal for the study of the pathophysiology of human PD. 
Instead, insight will likely emanate from a combination of different 
approaches and preclinical models, toxin-based as well as genetic, to study 
various aspects of the disease etiology. 
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Figures for Chapter III. 
 
 
 
 
Figure I- MitoPark and Wild Type mice have similar a-wave implicit times under the scotopic 
and photopic conditions tested. LMS = Least Mean Squares from the mixed model analysis. 
(p> 0.05). 
 
 
 
 
 
 
 
 
Figure II- MitoPark and Wild Type mice have similar a-wave amplitudes in the scotopic and 
photopic conditions tested. LMS = Least Mean Squares from the mixed model analysis. 
(p>0.05). 
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Figure III- There is a general trend (although not significant) of MP mice having prolonged 
implicit times of b-wave formation for most time points when compared to WT mice except 
at the highest 
light intensity evaluated under scotopic conditions. Interestingly, B-wave implicit time 
showed a tendency of shortening in MP mice at the highest light intensity measured (10 
cd·s/m
2
) (p=0.05), while the WT mice exhibited longer implicit times. 
 
 
 
 
Figure IV: There was no statistically significant difference (p>0.05) between the mean b-
wave amplitudes of the MP and WT mice, when recorded in response to all stimulus light 
intensities, under scotopic conditions. 
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Figure V- The graphs represent implicit time (A) and amplitude (B) for b-wave formation at 
3 cd·s/m
2 
tested under photopic conditions. LMS = Least Mean Squares from the mixed 
model analysis. (p>0.05). 
 
 
 
 
Figure VI A& B- Histological analysis of the mice groups: Representative Slides of 
Mice Retina for WT (A) and MP (B) Mouse Groups at 40X. The slides were stained with 
hematoxylin and eosin (H&E) and evaluated by light microscopy, 40X. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Table I- Histological measurements of mice retinas (µm). 
The results are tabulated as the average (standard deviation) of each mouse group (5 
measurements each animal). Although mean retinal thickness was less in the MP mouse, 
the difference was not statistically different (p>0.05). 
 
 Wild Type Mice MitoPark Mice 
Retina Thickness 126.94 (±20.61) 112.63 (±22.44) 
INL Thickness 27.34 (±9.62) 23.17 (±4.48) 
IPL Thickness 43.61 (±11.57) 34.41 (±7.33) 
ONL Thickness 42.08 (±9.66) 37.55 (±6.08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure VII- Summary of the structural changes in retinal layers from WT and 
MP mice. The measured retinal layers are designed as Whole Retinal 
Thickness (Full Thickness), inner nuclear layer thickness (INL), inner 
plexiform layer thickness (IPL), outer nuclear layer thickness (ONL). Refer 
to table 1 for measurement values. 
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Figure VIII- Representative Slides of Mouse Retinas for WT (A) and MP (B) 
mice using Tyrosine Hydroxylase Immunoreactivity. (40x) There were no 
differences appreciated between TH staining between mouse groups. 
 
 
 
 
 
 
Figure IX- There is a general trend (although not significant) of MP mice having prolonged  
implicit times of b-wave formation for most time points when compared to WT mice except 
at the 
highest light intensity evaluated under scotopic conditions. B-wave implicit time showed  
significant shortening in the MP mice at the highest light intensity measured (10 cd·s/m
2
) 
(p=0.03) compared to WT when retinal thickness was included as a covariate in the linear 
mixed model . 
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Figure X. There is a significant difference in mean implicit time between mouse 
groups at the highest light intensity tested, when evaluated using a t-test. 
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CHAPTER IV. GENERAL CONCLUSIONS 
 
 
 
Summary and Recommendations for Further Research 
 
 
 
Parkinson’s disease is currently regarded as the second most 
common degenerative disorder of the aging brain after Alzheimer’s disease. 
Although most often associated with its classic phenotypical motor 
symptoms such as tremor at rest, bradykinesia and postural instability, 
research over the past thirty years has investigated the presence of non-
motor manifestations that go beyond the classic neurodegenerative disease 
description. The non-motor manifestations of PD can cause significant 
disability in human patients and can complicate disease therapies. 
Early detection of PD may be beneficial as early recognition may slow 
down progression of disease development by implementation of medical 
therapies. Electroretinography and even certain imaging modalities such as 
optical coherence tomography is minimally invasive for patients. Such 
diagnostic equipment could aid in reaching diagnoses and also be used to 
evaluate response to medical therapy (like Levopa), as an investigator 
could evaluate changes in implicit time or amplitude of retinal waves during 
therapy trials. A better appreciation of how structural and physiological 
components of the eye are affected in PD patients is imperative to aid in 
improvement in the quality of life in PD patients. 
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There are many areas in which this initial study could be expanded 
upon. For example, further studies may have more definitive results if more 
mice are included in each group (i.e., wild type and MitoPark mouse 
groups). The anesthesia protocol should be reevaluated, as improvements in 
the anesthetic protocol may aid in the ability to perform electroretinography 
in older MP mice with a decreased risk of anesthetic complications. 
Furthermore, testing and assessment of the inner retina, through the use of 
pattern electroretinogram protocols could be investigated, as pattern ERGs 
give us information about contrast sensitivity and visual acuity more so than 
the flash ERG. 
 
 
Concluding remarks 
 
 
 
We have described PD and common associated visual symptoms in 
humans with the neurodegenerative disease. Furthermore we characterized 
the flash electroretinogram and retinal histology and found alterations in 
implicit time of the b-wave formation in the MP mouse. This allows us to 
move forward with similar investigations in this mouse model, as well as 
other mouse models, to improve the knowledge of PD animal models. 
